Kimberly Loo1,2, Gabrielle Gauvin1, Iman Soliman1, Madelyn Renzetti1,2, Mengying Deng3, Eric Ross3, Biao Luo4, Hong Wu4, Sanjay Reddy1, Anthony J Olszanski5, Jeffrey M Farma1. 1. Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. 2. Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA. 3. Department of Statistics, Fox Chase Cancer Center, Philadelphia, PA, USA. 4. Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA, USA. 5. Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.
Abstract
INTRODUCTION: Considerable advances in melanoma have been realized through immunotherapy. The principal aim was to determine whether primary tumor characteristics or next-generation sequencing (NGS) could serve as markers of immunotherapy response. METHODS AND RESULTS: The study cohort consisted of 67 patients who received immunotherapy for recurrent or metastatic melanoma and for whom primary tumor biopsies and pathology reports were available. A subset of 59 patient tumors were profiled using an NGS panel of 50 cancer-related genes. Objective response rate to immunotherapy was assessed using RECIST v1.1 criteria. Progression-free survival (PFS) and overall survival (OS) were used as endpoints. Lymphovascular invasion (LVI) strongly correlated with an increased proportion of immunotherapy responders (p = .002). PFS interval (p = .003) and OS (p = .036) were significantly higher in patients with LVI. NRAS mutation was more strongly correlated with an increased proportion of immunotherapy responders (p =.050). PFS was significantly higher in patients with NRAS mutation (p = .042); no difference in OS (p = .111). DISCUSSION: This analysis demonstrates an association between lymphovascular invasion and immunotherapy response. Additionally, NGS mutation analysis demonstrated a potential association between NRAS mutations and immunotherapy response.
INTRODUCTION: Considerable advances in melanoma have been realized through immunotherapy. The principal aim was to determine whether primary tumor characteristics or next-generation sequencing (NGS) could serve as markers of immunotherapy response. METHODS AND RESULTS: The study cohort consisted of 67 patients who received immunotherapy for recurrent or metastatic melanoma and for whom primary tumor biopsies and pathology reports were available. A subset of 59 patienttumors were profiled using an NGS panel of 50 cancer-related genes. Objective response rate to immunotherapy was assessed using RECIST v1.1 criteria. Progression-free survival (PFS) and overall survival (OS) were used as endpoints. Lymphovascular invasion (LVI) strongly correlated with an increased proportion of immunotherapy responders (p = .002). PFS interval (p = .003) and OS (p = .036) were significantly higher in patients with LVI. NRAS mutation was more strongly correlated with an increased proportion of immunotherapy responders (p =.050). PFS was significantly higher in patients with NRAS mutation (p = .042); no difference in OS (p = .111). DISCUSSION: This analysis demonstrates an association between lymphovascular invasion and immunotherapy response. Additionally, NGS mutation analysis demonstrated a potential association between NRAS mutations and immunotherapy response.
Authors: Caroline Robert; Jacob Schachter; Georgina V Long; Ana Arance; Jean Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Omid Hamid; Christine Mateus; Ronnie Shapira-Frommer; Michele Kosh; Honghong Zhou; Nageatte Ibrahim; Scot Ebbinghaus; Antoni Ribas Journal: N Engl J Med Date: 2015-04-19 Impact factor: 91.245
Authors: Douglas B Johnson; Christine M Lovly; Marisa Flavin; Katherine S Panageas; Gregory D Ayers; Zhiguo Zhao; Wade T Iams; Marta Colgan; Sarah DeNoble; Charles R Terry; Elizabeth G Berry; A John Iafrate; Ryan J Sullivan; Richard D Carvajal; Jeffrey A Sosman Journal: Cancer Immunol Res Date: 2015-03 Impact factor: 11.151
Authors: Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol Journal: N Engl J Med Date: 2012-06-02 Impact factor: 91.245
Authors: Amanda W Lund; Marek Wagner; Manuel Fankhauser; Eli S Steinskog; Maria A Broggi; Stefani Spranger; Thomas F Gajewski; Kari Alitalo; Hans P Eikesdal; Helge Wiig; Melody A Swartz Journal: J Clin Invest Date: 2016-08-15 Impact factor: 14.808
Authors: Jeffrey S Weber; Ragini Reiney Kudchadkar; Bin Yu; Donna Gallenstein; Christine E Horak; H David Inzunza; Xiuhua Zhao; Alberto J Martinez; Wenshi Wang; Geoffrey Gibney; Jodi Kroeger; Cabell Eysmans; Amod A Sarnaik; Y Ann Chen Journal: J Clin Oncol Date: 2013-10-21 Impact factor: 44.544
Authors: Anne Reiman; Hugh Kikuchi; Daniela Scocchia; Peter Smith; Yee Wah Tsang; David Snead; Ian A Cree Journal: BMC Cancer Date: 2017-02-22 Impact factor: 4.430